NCT03930680View on ClinicalTrials.gov

Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

June 11, 2024

Study Completion Date

June 11, 2025

Conditions

Degradation of Top2b and Top2a in Human by DexrazoxaneTime Course and Degradation of Top2b in Human by DexrazoxaneEffects of Dexrazoxane on Healthy Human

Interventions

DRUG

Dexrazoxane

One dose of dexrazoxane

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Arkansas

OTHER

NCT03930680 - Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane | Biotech Hunter | Biotech Hunter